WALTHAM, Mass.--(BUSINESS WIRE)--Thermedical®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today it has received $3 million in grant funding (1R44HL169112) from the National Heart, Lung, and Blood Institute, a part of the National Institutes of Health, to fund its FDA-approved clinical trial at seven centers in the U.S.

马萨诸塞州沃尔瑟姆-治疗室性心律失常的热消融系统开发商Thermedical®今天宣布，它已从美国国家心肺血液研究所获得300万美元的拨款（1R44HL169112），美国国立卫生研究院的一部分，为美国7个中心的FDA批准的临床试验提供资金。

and Canada using the SERF Ablation System with the Durablate® Catheter to treat ventricular tachycardia (VT). VT is an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide. Sudden cardiac death kills 325,000 adults in the U.S. every year1..

和加拿大使用SERF消融系统和Durablate®导管治疗室性心动过速（VT）。VT是异常快速的心律，是全球心脏猝死的主要原因。美国每年有325000名成年人死于心源性猝死1。。

The company also announced it will showcase its novel Saline Enhanced Radiofrequency (SERF) Ablation System with the Durablate Catheter at the 18th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy, October 13–14, 2023, at the Bellevue Hotel Philadelphia.

该公司还宣布，它将在2023年10月13日至14日在费城Bellevue酒店举行的第18届室性心律失常：病理生理学和治疗年度国际研讨会上展示其带有Durablate导管的新型盐水增强射频（SERF）消融系统。

“We are honored to receive this generous grant from the NIH to fund the treatment of VT using our SERF Ablation System in patients who have run out of treatment options for their VT episodes,” said Michael Curley, Ph.D., FHRS, co-founder and CEO of Thermedical. “In our most recent multi-center trial, 38 of 41 participants experienced immediate elimination of their clinical VT at the end of the procedure, and therapies such as shock or pace regulation were either substantially reduced or completely eliminated in 73% of these patients during the six-month follow-up.”.

Michael Curley博士，FHRS，共同创始人兼首席执行官Michael Curley博士说：“我们很荣幸地得到美国国立卫生研究院的慷慨资助，以资助使用我们的SERF消融系统治疗VT的患者，这些患者的VT发作已经没有治疗选择。”。“在我们最近的多中心试验中，41名受试者中有38名在手术结束时立即消除了临床室速，其中73%的患者在休克或起搏调节等治疗中大大减少或完全消除在六个月的随访期间“。

SERF ablation with the Durablate catheter is being evaluated as a treatment option for patients with ventricular arrhythmias resistant to antiarrhythmic drugs or standard ablation procedures. SERF ablation provides a new, more efficient form of biological heat transfer than conventional ablation methods.

使用Durablate导管进行SERF消融正在被评估为抗心律失常药物或标准消融手术的室性心律失常患者的治疗选择。与传统的消融方法相比，SERF消融提供了一种新的，更有效的生物传热形式。

The Durablate catheter delivers energy with a high level of accuracy to treat tissue deeper in the heart wall where life-threatening arrhythmias that cause VT are often located..

Durablate导管以高精度输送能量，以治疗心脏壁深处的组织，这些组织通常位于导致VT的危及生命的心律不齐的地方。。

'Episodes of ventricular tachycardia reduce the quality of life for many patients with implantable defibrillators,' said William G. Stevenson, Professor of Medicine, Vanderbilt University Medical Center. 'SERF ablation is a new approach that has the potential to improve treatment of this arrhythmia.

范德比尔特大学医学中心医学教授威廉·史蒂文森（William G.Stevenson）说：“室性心动过速发作会降低许多植入式除颤器患者的生活质量。”SERF消融是一种有可能改善这种心律失常治疗的新方法。

This trial will provide important information about the safety of this promising approach and offer hope to people whose VT has not been controllable with available therapies.'.

该试验将提供有关这种有希望的方法的安全性的重要信息，并为VT无法通过现有疗法控制的人提供希望。

Implantable Cardioverter Defibrillators (ICDs)—electronic devices that continually monitor a patient’s heart rhythm—are the current treatment for patients suffering from VT. During a VT episode, the ICD delivers energy to the heart muscle via a powerful shock or antitachycardia pacing to help the heart beat normally again.

植入式心脏复律除颤器（ICD）-持续监测患者心律的电子设备是目前VT患者的治疗方法。在VT发作期间，ICD通过强烈的休克或抗心动过速起搏向心肌提供能量以帮助心脏正常跳动。

Today, VT patients with ICDs who experience VT episodes may be treated with conventional RF ablation, a lengthy procedure with a moderate success rate of approximately 50%..

今天，患有VT发作的ICD的VT患者可以用常规RF消融治疗，这是一个漫长的过程，成功率约为50%。。

About Thermedical

关于热疗

Thermedical is a privately held company founded by Massachusetts Institute of Technology (MIT) Hyperthermia Center alumni Michael G. Curley, Ph.D., and Patrick S. Hamilton, Ph.D., based in Waltham, Mass. Under a Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) Award, multiple NIH Small Business Innovation Research (SBIR) Grants, and Series A venture funding, the company has developed thermal-ablation systems to treat ventricular tachycardia (VT) and solid tumors.

Thermedical是一家私营公司，由麻省理工学院（MIT）热疗中心校友Michael G.Curley博士和Patrick S.Hamilton博士创立，总部设在马萨诸塞州沃尔瑟姆。马萨诸塞州生命科学中心小企业匹配授予（SBMG）奖，多项NIH小企业创新研究（SBIR）资助和a系列风险资助，该公司开发了热消融系统来治疗室性心动过速（VT）和实体瘤。

For more information, visit www.thermedical.com..

欲了解更多信息，请访问www.thermedical.com。。

______________

______________

1 https://www.webmd.com/heart-disease/sudden-cardiac-death

1 https://www.webmd.com/heart-disease/sudden-cardiac-death